Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.
about
Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trialsTreatment-refractory anxiety; definition, risk factors, and treatment challengesOptimizing treatments for anxiety by age and geneticsExploring exercise as an avenue for the treatment of anxiety disordersEpisodic memories in anxiety disorders: clinical implicationsPharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disordersCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersTreatment of anxiety disorders in epilepsy: an evidence-based approachThreat reappraisal as a mediator of symptom change in cognitive-behavioral treatment of anxiety disorders: a systematic reviewThe evidence-based pharmacotherapy of social anxiety disorderIndividual differences in recovery from traumatic fearRegulation of emotional response in juvenile monkeys treated with fluoxetine: MAOA interactionsAn Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical TrialsExercise Augmentation of Exposure Therapy for PTSD: Rationale and Pilot Efficacy DataPsychotherapy Augmentation through Preconscious Priming.Chronic antidepressant treatment impairs the acquisition of fear extinction.Pharmacological enhancement of fear reduction: preclinical models.Enhancing exposure-based therapy from a translational research perspective.Group cognitive behavior therapy for Japanese patients with social anxiety disorder: preliminary outcomes and their predictorsPharmacotherapy for social anxiety disorder: a systematic review.Spatiotemporal dissociation of brain activity underlying threat and reward in social anxiety disorderD-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorderA placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorderD-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders.Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and PreventionEvidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Social Mishap Exposures for Social Anxiety Disorder: An Important Treatment Ingredient.D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variablesRandomized controlled trial of cognitive behavioral therapy and acceptance and commitment therapy for social phobia: outcomes and moderatorsWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders.Resting state amygdala-prefrontal connectivity predicts symptom change after cognitive behavioral therapy in generalized social anxiety disorderWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Psychological group-treatments of social anxiety disorder: a meta-analysis.Transfer of manualized Short Term Psychodynamic Psychotherapy (STPP) for social phobia into clinical practice: study protocol for a cluster-randomised controlled trialImpairments in goal-directed actions predict treatment response to cognitive-behavioral therapy in social anxiety disorder.Treatment of co-occurring anxiety disorders and substance use disorders.Fear and anxiety from principle to practice: implications for when to treat youth with anxiety disordersNeural response during attentional control and emotion processing predicts improvement after cognitive behavioral therapy in generalized social anxiety disorder.A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder.Current management of obsessive and phobic states.
P2860
Q22241101-6E9808D4-32AB-4366-BD5C-3408D7B27142Q26798229-3668FC25-E5AE-4E40-BDC0-26EE5775F1EFQ26823694-3829E4FA-1EC9-467F-9FC0-1FF23B5D82ABQ27001236-7A90B7E7-7F07-4DF1-9616-21B72B709652Q27001902-9861F502-DEC0-4651-AA25-422C91847077Q27006437-AD23F54B-F2A6-4023-8CA3-420D049D3F52Q27009995-A3553B54-1582-49B6-BFB5-004409C83E3CQ27013563-1CBBB52D-835C-421B-8680-B3AE4AB3DEE9Q27021492-04DAB517-D54D-443D-8E44-D369F848ED64Q28262456-55541E4B-FC58-44A4-A780-C5C6B9D7ADB1Q28389310-8CE69978-013D-461B-9980-31CF3F5E8B5CQ28396360-E3A73EF9-31D6-41B0-958B-9D08952F8BA4Q30375098-0CD8EFD5-EC23-45D2-A223-9F80481D52F0Q30382252-FD256989-C1CF-432B-BA65-1A5AFDAE82EAQ30428423-033B2408-5DEF-4570-8608-FE10BBDBEFA4Q30437449-7D0A26A5-80AF-4C6C-BCB1-A620169F858DQ30462825-C12DC28C-8FBB-48FE-9BBC-9C946F025B4CQ30493574-A5EAEFF9-9A57-4A55-BE65-43FF75D91147Q33309353-4614AB1B-F3B8-4B1E-972B-0D5864B21213Q33319625-E2548D3F-40B2-4C19-A279-CB49FC7C13E4Q33561721-53BFCD06-955C-4A6E-90D3-AA8FE7FA2F38Q33760626-4D3A4815-F10C-4FC6-A5CF-3AA467046FEBQ33798078-DDD35926-F6AF-4FAA-BDBA-436E879735BCQ34350942-84562F4A-8E62-460A-9C15-60FD1F6BB1BEQ34359824-E8925AD3-25F1-4C65-B8A7-DC09D43E7216Q34465555-8851CF97-C835-4FA8-B5D7-BA8E6AAFAFD0Q34549316-F32AE355-B8FD-419E-A150-59004FCBC0D2Q34562562-4346E67A-004E-4631-B81C-843BDC332371Q34572395-78C713DD-C5D2-4D57-BEAF-B270F5C63801Q34584223-A0C2C11B-CF45-4B43-924B-7589F1793506Q34769176-698A0978-6FBE-4BEF-9CBB-3A2A3B2A1EADQ34865036-0620B5DA-9021-4FDA-A4D9-DE25D052FFE5Q35048173-B1F6CADD-C367-43A3-B464-53DA7B47879FQ35069250-5701274F-1ED1-4C43-9D19-865BCE2D2910Q35146843-782D2109-68A8-4913-A661-7C80AC645AEFQ35166440-1773FFFA-7355-420B-AC26-2750CD4A0A39Q35213969-C1E3DE42-6B0A-4CCE-B45A-E82337F61E0DQ35223534-576ED4C6-A70F-4E35-BAED-142F75FC6A1FQ35320221-A4CB8F88-4B52-405D-91FB-DBDD0B7246B7Q35327098-543892AF-61FD-494A-8F25-EF155A05158B
P2860
Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@ast
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@en
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@nl
type
label
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@ast
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@en
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@nl
prefLabel
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@ast
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@en
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@nl
P2093
P1433
P1476
Fluoxetine, comprehensive cogn ...... in generalized social phobia.
@en
P2093
Edna B Foa
Francis J Keefe
Jill S Compton
Jonathan R T Davidson
Kathryn M Connor
Kishore M Gadde
Martin E Franklin
P304
P356
10.1001/ARCHPSYC.61.10.1005
P407
P577
2004-10-01T00:00:00Z